Friedemann Paul, MD, Charité-Universitätsmedizin Berlin, Berlin, Germany, shares his highlights from the American Academy of Neurology (AAN) Annual Meeting. Follow-up data from open-label extensions for all three newly approved NMOSD treatments are available and were discussed at the meeting. The new MOGAD diagnostic criteria were also an important topic at the meeting. The recently published diagnostic criteria allow better discrimination between MOGAD and multiple sclerosis as well as serum-negative NMOSD. This interview took place at the AAN Annual Meeting 2023 in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.